TC-G 1005 is a potent, selective and orally active agonist of the BA receptor Takeda G protein-coupled receptor 5 (TGR5), with EC50s of 0.72 and 6.2 nM for hTGR5 and mTGR5, respectively. TC-G 1005 can reduce glucose levels in vivo.
IC50&Target
IC50: 0.72 nM (hTGR5); 6.2 nM (mTGR5)
体外研究
TC-G 1005 activates human and mouse TGR5 with EC50s of 0.72 nM and 6.2 nM, respectively.
体内研究
TC-G 1005 (25-100 mg/kg; a single p.o.) stimulates GLP-1 secretion in imprinting control region (ICR) mice.
TC-G 1005 (50 mg/kg; a single p.o.) causes a 49% reduction in blood glucose AUC0-120 min in ICR mice.
TC-G 1005 (50 mg/kg; a single p.o.) significantly reduces blood glucose at 4, 6, 10, and 24 h in db/db mice.
TC-G 1005 (5 mg/kg; p.o.) exhibits rather low plasma exposure, with a Cmax of 56 ng/mL and a t1/2 of 1.5 in rats.
Animal Model:
Male ICR mice
Dosage:
25, 50, 100 mg/kg
Administration:
A single p.o.
Result:
Increased the plasma active GLP-1 levels by 31, 96, and 282% at doses of 25, 50, and 100 mg/kg, respectively.
分子式
C25H25N3O2
分子量
399.48
CAS号
1415407-60-1
运输条件
Room temperature in continental US; may vary elsewhere.